- Home
- Publications
- Publication Search
- Publication Details
Title
Azacitidine
Authors
Keywords
-
Journal
DRUGS
Volume 72, Issue 8, Pages 1111-1136
Publisher
Springer Nature
Online
2012-05-10
DOI
10.2165/11209430-000000000-00000
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Phase 2 clinical trial of 5-azacitidine, valproic acid, and all-trans retinoic acid in patients with high-risk acute myeloid leukemia or myelodysplastic syndrome
- (2015) Oncotarget
- MDS-specific comorbidity index is useful to identify myelodysplastic patients who can have better outcome with 5-azacitidine
- (2012) M. Breccia et al. HAEMATOLOGICA
- Azacitidine adverse effects in patients with myelodysplastic syndromes
- (2011) L. San Miguel Amigo et al. ADVANCES IN THERAPY
- Myelodysplastic syndromes: 2011 update on diagnosis, risk-stratification, and management
- (2011) Guillermo Garcia-Manero AMERICAN JOURNAL OF HEMATOLOGY
- Platelet doubling after the first azacitidine cycle is a promising predictor for response in myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML) patients in the Dutch azacitidine compassionate named p
- (2011) Lieke H. van der Helm et al. BRITISH JOURNAL OF HAEMATOLOGY
- Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher-risk myelodysplastic syndromes
- (2011) Lewis R. Silverman et al. CANCER
- Azacitidine for the treatment of patients with acute myeloid leukemia
- (2011) Luca Maurillo et al. CANCER
- Phase I and II study of azacitidine in Japanese patients with myelodysplastic syndromes
- (2011) Toshiki Uchida et al. CANCER SCIENCE
- Cytogenetic response is not a prerequisite for clinical response in patients with myelodysplastic syndromes treated with azacitidine
- (2011) Shane A. Gangatharan et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Outcome of High-Risk Myelodysplastic Syndrome After Azacitidine Treatment Failure
- (2011) Thomas Prébet et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Study of Oral Azacitidine in Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, and Acute Myeloid Leukemia
- (2011) Guillermo Garcia-Manero et al. JOURNAL OF CLINICAL ONCOLOGY
- Low-Dose Decitabine Versus Best Supportive Care in Elderly Patients With Intermediate- or High-Risk Myelodysplastic Syndrome (MDS) Ineligible for Intensive Chemotherapy: Final Results of the Randomized Phase III Study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group
- (2011) Michael Lübbert et al. JOURNAL OF CLINICAL ONCOLOGY
- DNA Methylation Changes Following 5-azacitidine Treatment in Patients with Myelodysplastic Syndrome
- (2011) Huong Thi Thanh Tran et al. JOURNAL OF KOREAN MEDICAL SCIENCE
- Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial
- (2011) U Platzbecker et al. LEUKEMIA
- Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias
- (2011) R Itzykson et al. LEUKEMIA
- Azacitidine in patients with acute myeloid leukemia medically unfit for or resistant to chemotherapy: a multicenter phase I/II study
- (2011) Haifa K. Al-Ali et al. LEUKEMIA & LYMPHOMA
- 177 UK experience of azacitidine therapy in patients with myelodysplastic syndromes
- (2011) S. Killick et al. LEUKEMIA RESEARCH
- 175 Czech MDS Group experience with azacitidine in treatment of high risk MDS and AML patients
- (2011) A. Jonasova et al. LEUKEMIA RESEARCH
- 82 Favourable outcome of young patient with t-MDS secondary to breast cancer treatment using azacitidine as induction therapy before allo-BMT
- (2011) G. Binotto et al. LEUKEMIA RESEARCH
- 102 Azacytidine as a bridge to haploidentical bone marrow transplant in a patient with hypocellular myelodysplasia with monosomy 7
- (2011) S.K. Rana et al. LEUKEMIA RESEARCH
- 286 The presence of aberrant myeloid progenitors predicts overall survival in intermediate-2 and high risk myelodysplastic syndromes upon treatment with azacitidine
- (2011) C. Alhan et al. LEUKEMIA RESEARCH
- 317 Influence of mild bone marrow fibrosis on response of int-2/high risk MDS patients to 5-azacitidine
- (2011) A. Sanna et al. LEUKEMIA RESEARCH
- Azacytidine and Decitabine Induce Gene-Specific and Non-Random DNA Demethylation in Human Cancer Cell Lines
- (2011) Sabine Hagemann et al. PLoS One
- Treatment of Higher-Risk Myelodysplastic Syndrome
- (2011) Guillermo Garcia-Manero SEMINARS IN ONCOLOGY
- Azacitidine for treatment of patients with myelodysplastic syndromes (MDS): practical recommendations of the German MDS Study Group
- (2010) Katharina Götze et al. ANNALS OF HEMATOLOGY
- Predictive value of pretreatment risk group and baseline LDH levels in MDS patients receiving azacitidine treatment
- (2010) Joon Ho Moon et al. ANNALS OF HEMATOLOGY
- Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine
- (2010) R. Itzykson et al. BLOOD
- Induction of a CD8+ T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia
- (2010) O. Goodyear et al. BLOOD
- Prolonged responses in patients with MDS and CMML treated with azacitidine and etanercept
- (2010) Bart L. Scott et al. BRITISH JOURNAL OF HAEMATOLOGY
- Prolonged survival with improved tolerability in higher-risk myelodysplastic syndromes: azacitidine compared with low dose ara-C
- (2010) Pierre Fenaux et al. BRITISH JOURNAL OF HAEMATOLOGY
- Azacitidine for the treatment of lower risk myelodysplastic syndromes
- (2010) Pellegrino Musto et al. CANCER
- Activity of azacitidine in chronic myelomonocytic leukemia
- (2010) Rubens Costa et al. CANCER
- Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome
- (2010) Marcos de Lima et al. CANCER
- Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy
- (2010) Elias Jabbour et al. CANCER
- In vitro assessment of cytochrome P450 inhibition and induction potential of azacitidine
- (2010) Yong Chen et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Feasibility of Therapy With Hypomethylating Agents in Patients With Renal Insufficiency
- (2010) G. Nicolas Batty et al. Clinical Lymphoma Myeloma & Leukemia
- Effects of azacitidine compared with conventional care regimens in elderly (≥75 years) patients with higher-risk myelodysplastic syndromes
- (2010) John F. Seymour et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- A phase I biological study of azacitidine (VidazaTM) to determine the optimal dose to inhibit DNA methylation
- (2010) Ilan Bernstein et al. Epigenetics
- Risk stratification based on both disease status and extra-hematologic comorbidities in patients with myelodysplastic syndrome
- (2010) M. G. Della Porta et al. HAEMATOLOGICA
- Phase I Combination Trial of Lenalidomide and Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes
- (2010) Mikkael A. Sekeres et al. JOURNAL OF CLINICAL ONCOLOGY
- Synergistic induction of PI-PLCβ1 signaling by azacitidine and valproic acid in high-risk myelodysplastic syndromes
- (2010) M Y Follo et al. LEUKEMIA
- Practical use of azacitidine in higher-risk myelodysplastic syndromes: An expert panel opinion
- (2010) Pierre Fenaux et al. LEUKEMIA RESEARCH
- A Comparison of Azacitidine and Decitabine Activities in Acute Myeloid Leukemia Cell Lines
- (2010) Paul W. Hollenbach et al. PLoS One
- Safety and efficacy of azacitidine in myelodysplastic syndromes
- (2010) Carlos Vigil et al. Drug Design Development and Therapy
- A phase II study of 5-day intravenous azacitidine in patients with myelodysplastic syndromes
- (2009) Mike G. Martin et al. AMERICAN JOURNAL OF HEMATOLOGY
- How I treat patients with myelodysplastic syndromes
- (2009) R. M. Stone BLOOD
- Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies
- (2009) T. E. Fandy et al. BLOOD
- MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation
- (2009) M. E. Figueroa et al. BLOOD
- 5-Azacitidine for myelodysplasia before allogeneic hematopoietic cell transplantation
- (2009) T Field et al. BONE MARROW TRANSPLANTATION
- Valproic Acid at Therapeutic Plasma Levels May Increase 5-Azacytidine Efficacy in Higher Risk Myelodysplastic Syndromes
- (2009) M. T. Voso et al. CLINICAL CANCER RESEARCH
- Hematologic Response to Three Alternative Dosing Schedules of Azacitidine in Patients With Myelodysplastic Syndromes
- (2009) Roger M. Lyons et al. JOURNAL OF CLINICAL ONCOLOGY
- Azacitidine Prolongs Overall Survival Compared With Conventional Care Regimens in Elderly Patients With Low Bone Marrow Blast Count Acute Myeloid Leukemia
- (2009) Pierre Fenaux et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study
- (2009) Pierre Fenaux et al. LANCET ONCOLOGY
- The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells
- (2009) C Flotho et al. LEUKEMIA
- Reduction of phosphoinositide-phospholipase C beta1 methylation predicts the responsiveness to azacitidine in high-risk MDS
- (2009) M. Y. Follo et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Myelodysplastic syndromes
- (2008) S. D. Nimer BLOOD
- Mechanisms of resistance to 5-aza-2'-deoxycytidine in human cancer cell lines
- (2008) T. Qin et al. BLOOD
- Aberrant DNA methylation is a dominant mechanism in MDS progression to AML
- (2008) Y. Jiang et al. BLOOD
- Hypomethylation and apoptosis in 5-azacytidine–treated myeloid cells
- (2008) Rasheed Khan et al. EXPERIMENTAL HEMATOLOGY
- Myelodysplastic syndromes: biology and treatment
- (2008) M. Jädersten et al. JOURNAL OF INTERNAL MEDICINE
- Activity of decitabine in patients with myelodysplastic syndrome previously treated with azacitidine
- (2008) Gautam Borthakur et al. LEUKEMIA & LYMPHOMA
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More